Skip to main content

Table 1 Demographic and clinical characteristics of melanoma patients treated with immunotherapy

From: Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients

Variable

Number of patients (n = 18)

Age (years)

Median (range)

41 (25–67)

Gender

 Male

10 (55.5 %)

 Female

8 (44.4 %)

Type of immunotherapy

 TriMixIpi

11 (61.1 %)

 Ipi

7 (38.8 %)

Response to immunotherapy

 DB

5 (27.7 %)

 NB

13 (72.2 %)

  1. Ipi Ipilimumab;TriMixIpi TriMixDC combined with Ipi; TriMixDC DC electroporated with mRNA encoding CD70, CD40L and a constitutively active toll-like receptor 4, co-electroporated with mRNA encoding full-length MAGE-A3, MAGE-C2, tyrosinase and gp100; DB durable clinical benefit; NB no clinical benefit